Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
S

Optimizing Therapy for ER+ Metastatic Breast Cancer: CDK 4/6 + Endocrine Therapy as 1st Line, Everolimus-Exemestane PI3K as a Reasonable Options for Mutant Patients

By Xth Eurasian Hematology-Oncology Congress FEATURING Sema Sezgin Göksu
By Xth Eurasian Hematology-Oncology Congress FEATURING Sema Sezgin Göksu
0 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Breast
06:46
Xth Eurasian Hematology-Oncology Congress

Systemic Therapy in Early HER2+ Breast Cancer: More Benefit w/Neoadj…

Feat. C. Arslan
23:24
Xth Eurasian Hematology-Oncology Congress

Systemic Adjuvant Therapy in Early HER2+ Breast Cancer: Escalating w…

Feat. C. Arslan
09:24
Xth Eurasian Hematology-Oncology Congress

Evolving Approaches in Systemic Therapy for TNBC in Adjuvant Setting…

Feat. O. Er
23:29
Xth Eurasian Hematology-Oncology Congress

Systemic Therapy for TNBC in Neoadjuvant Setting: Initial Treatment …

Feat. O. Er
32:43
Xth Eurasian Hematology-Oncology Congress

Adjuvant Therapy in ER+ / HER2- Early Breast Cancer: Is Chemotherapy…

Feat. M. Kaplan
15:29
Xth Eurasian Hematology-Oncology Congress

Optimizing Therapy for ER+ Metastatic Breast Cancer: CDK 4/6 + Endoc…

Feat. S. Göksu
10:36
Xth Eurasian Hematology-Oncology Congress

Overcoming Resistance in HER2+ Metastatic Breast Cancer: Single Anti…

Feat. S. Uzunoğlu
13:37
Xth Eurasian Hematology-Oncology Congress

Overcoming Resistance in HER2+ Metastatic Breast Cancer: Inhibiting …

Feat. S. Uzunoğlu
18:51
Xth Eurasian Hematology-Oncology Congress

PARPi as the Emerging Treatment Strategy in BRCA+ Metastatic TNBC: I…

Feat. O. Dizdar